Immunovant (IMVT) Projected to Post Quarterly Earnings on Monday

Immunovant (NASDAQ:IMVT) is expected to be posting its Q2 2026 results before the market opens on Monday, November 10th. Analysts expect Immunovant to post earnings of ($0.73) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earningoverview page for the latest details on the call scheduled for Monday, November 10, 2025 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.09. During the same period in the previous year, the business posted ($0.60) earnings per share. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Stock Performance

Shares of IMVT stock opened at $24.68 on Monday. The stock’s fifty day moving average is $17.06 and its two-hundred day moving average is $16.21. The firm has a market capitalization of $4.30 billion, a P/E ratio of -8.66 and a beta of 0.60. Immunovant has a fifty-two week low of $12.72 and a fifty-two week high of $32.10.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Immunovant in a report on Tuesday, October 14th. JPMorgan Chase & Co. reduced their price target on Immunovant from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, September 30th. UBS Group lifted their price target on Immunovant from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, July 28th. Bank of America cut their price objective on Immunovant from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Finally, The Goldman Sachs Group raised Immunovant to a “hold” rating and set a $18.00 price objective for the company in a research report on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $28.78.

Insider Activity at Immunovant

In related news, insider Michael Geffner sold 2,595 shares of the business’s stock in a transaction that occurred on Wednesday, October 22nd. The stock was sold at an average price of $19.03, for a total transaction of $49,382.85. Following the completion of the sale, the insider owned 217,958 shares in the company, valued at $4,147,740.74. The trade was a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Jay S. Stout sold 2,520 shares of the business’s stock in a transaction that occurred on Wednesday, October 22nd. The shares were sold at an average price of $19.03, for a total value of $47,955.60. Following the completion of the sale, the chief technology officer owned 200,814 shares of the company’s stock, valued at approximately $3,821,490.42. This represents a 1.24% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 7,972 shares of company stock valued at $143,908. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IMVT. Adage Capital Partners GP L.L.C. grew its holdings in Immunovant by 2,086.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 463,600 shares of the company’s stock worth $7,418,000 after acquiring an additional 442,400 shares during the period. Goldman Sachs Group Inc. grew its holdings in Immunovant by 48.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock valued at $17,222,000 after purchasing an additional 329,354 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in Immunovant by 127.3% in the second quarter. Canada Pension Plan Investment Board now owns 414,800 shares of the company’s stock valued at $6,637,000 after purchasing an additional 232,300 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in Immunovant in the second quarter valued at $3,161,000. Finally, BNP Paribas Financial Markets grew its holdings in Immunovant by 144.3% in the second quarter. BNP Paribas Financial Markets now owns 298,170 shares of the company’s stock valued at $4,771,000 after purchasing an additional 176,121 shares during the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.